Exosome vs PDRN: What Aesthetic Buyers Should Know

Why Do Buyers Confuse Exosomes and PDRN?

Both categories sit in the same commercial space. Both are sold into aesthetic clinics and distributors. Both are often presented in the same supplier catalogue, in similar packaging, with similar marketing language. In some cases the same factory produces both. The result is that they are frequently treated as interchangeable procurement options, evaluated on the same price-per-unit basis and ordered against the same requisition.

That is a category error, and it is an expensive one. Exosomes and PDRN differ in molecular composition, in origin, and — critically for the people placing purchase orders — in how regulators classify them. A buyer who understands those differences can ask the right questions and hold defendable documentation. A buyer who does not will eventually import a product whose regulatory status nobody on the supply chain can state clearly.

This article is a procurement-side comparison. It covers what each category is, how it is classified in the US, Korea, and the EU, and what documentation a buyer should demand. It does not cover clinical use, and it deliberately avoids describing any expected outcome of any product.

---

What Each Category Actually Is

Exosomes

Exosomes are small extracellular vesicles that are secreted by cells and that carry proteins, lipids, and nucleic acids. In the aesthetic supply chain, the products sold under this label are typically derived from cell culture — most commonly mesenchymal stem cell sources — and are supplied in formats that include lyophilised powders, solutions, and gels.

The important procurement point is that an exosome product derived from human or animal cell sources and intended for introduction into the body is a biological product. Biological products carry a specific and heavy regulatory burden, and that burden does not disappear because a product is marketed for cosmetic rather than therapeutic use. This is where most of the compliance risk in this category sits.

PDRN and PN

PDRN stands for polydeoxyribonucleotide. PN stands for polynucleotide. Both are nucleic-acid-derived materials, and they are related but not identical — a distinction covered in a separate guide in this series. In practice, products in this family are supplied as injectable solutions and ampoules, and they are most established in the Korean market, where polynucleotide products have been authorised through a medical device pathway.

They are not cell-derived in the way exosome products are, and they are not biological products in the same regulatory sense. That difference is significant: a nucleic-acid-derived material and a cell-derived biological product do not land in the same regulatory bucket, and a buyer should never assume that evidence of one category’s status carries over to the other.

Comparison	Exosome products	PDRN / PN products
Molecular nature	Cell-derived extracellular vesicles	Nucleic-acid-derived material
Typical origin	Cell culture (often mesenchymal stem cell)	Nucleic-acid sources, processed
Common supply formats	Lyophilised powder, solution, gel	Injectable solution, ampoule
US regulatory status	No FDA-approved exosome product	No FDA-approved PN or PDRN injectable filler or skin booster
Korean regulatory status	Varies by specific product	MFDS-approved polynucleotide products exist via medical device pathway
EU regulatory status	ATMP framework where intended for therapeutic use	Classification depends on intended purpose and claims
Principal buyer risk	Unapproved-new-drug and unlicensed-biologic exposure	Misrepresented or ambiguous classification

---

The Regulatory Position, Stated Plainly

This is the part of the article that matters most, and it is worth stating without hedging.

United States — exosomes

The FDA has not approved any exosome product. Its enforcement position is documented in warning letters issued to suppliers, in which the agency has stated that exosome products offered for allogeneic use are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act, and unlicensed biological products under section 351(a)(1) of the Public Health Service Act. The FDA has also published a public safety notification concerning exosome products following reports of serious adverse events.

Warning letters are not a general policy statement — they are case-specific enforcement actions. But the legal theory applied in them is consistent and it applies to the category, not to one company. A buyer should read the absence of a warning letter as the absence of enforcement against a particular seller, not as evidence of approval.

Practical consequence: any supplier marketing an exosome product as FDA approved, FDA cleared, or FDA registered is making a claim the FDA has not made and cannot support. This is a reliable disqualifying signal in a supplier evaluation.

United States — PDRN and PN

The FDA has not approved any PN or PDRN injectable product as a dermal filler or skin booster. The materials the agency has approved for use in dermal fillers are limited to:

• Hyaluronic acid
• Collagen
• Calcium hydroxylapatite
• Poly-L-lactic acid
• Polymethylmethacrylate microspheres

PDRN and polynucleotides are not on that list. A supplier who describes a PDRN product as an approved filler material in the US market is misstating the regulatory position.

Korea — the polynucleotide pathway

Korea’s Ministry of Food and Drug Safety (MFDS) has approved polynucleotide-based products through a medical device pathway, and Korea is the largest single market for the category. This is genuinely relevant for buyers, for two reasons.

First, it demonstrates that an actual regulatory pathway exists and has been used. That is stronger evidence of product legitimacy than any marketing claim.

Second, and more important from a procurement standpoint: an MFDS authorisation is a Korean national decision. It has no force in the US, the EU, or any other market. A supplier who presents an MFDS approval as a global or US approval is not misrepresenting the Korean decision — they are misrepresenting its scope, which is a distinction worth being precise about in a supplier evaluation.

European Union — exosomes as ATMPs

In the EU, exosome-based products intended for therapeutic use fall within the advanced therapy medicinal products (ATMP) framework, administered centrally by the European Medicines Agency and assessed through the Committee for Advanced Therapies. ATMPs follow a centralised marketing authorisation route.

The practical point for importers: if a product is intended for therapeutic use, a cosmetic notification or a medical device marking is not a substitute for an ATMP marketing authorisation. Buyers should establish which framework a supplier believes applies before importing, and should be sceptical of a supplier who cannot answer the question.

Market size context

The polynucleotide injectable market is a real and growing commercial category, with published market estimates placing it in the hundreds of millions of US dollars and projecting substantial growth through the next decade. Market size is not a regulatory status — but it is a reason to expect that the category will attract increasing regulatory attention, not diminishing attention, over the period in which you hold inventory.

---

What This Means for Procurement

Regulatory status is not an abstraction for a buyer. It determines what you can hold, what you can say, and what your exposure is if a shipment is challenged. Four procurement consequences follow directly.

You cannot buy category status from a supplier. There is no certificate a supplier can provide that changes the FDA position on exosome products. Documentation proves that a product is what it claims to be; it does not create an approval that does not exist.

Classification must be stated in writing. For every product in either category, ask the supplier to state in writing: the exact regulatory classification the product is supplied under, the market in which that classification applies, and what the product is and is not approved or authorised for. A supplier who answers this question clearly and precisely is a different kind of counterparty from one who deflects.

Marketing language is a risk indicator. A supplier who describes these categories using assertion language that no regulator has endorsed is signalling how they approach compliance across their whole catalogue. That signal should be weighted heavily in a supplier evaluation, and it should be checked on a product other than the one you are considering.

Intended use drives classification. The same physical material can be classified differently depending on the intended purpose it is placed on the market for. Buyers should be explicit about the intended use they are purchasing for, and should confirm the classification matches that use — not assume the supplier has considered the question.

---

Documentation Checklist for Exosome and PDRN Products

Before ordering either category, confirm you hold each of the following. If any item cannot be produced, regard that as a procurement decision rather than an administrative gap.

• Quality management certification with the full scope text naming sterile manufacture and the relevant product category.
• Lot-specific Certificate of Analysis with measured numerical values, not pass/complies statements.
• Exact regulatory classification the product is supplied under, stated in writing.
• Applicable market or jurisdiction for that classification.
• Written statement of what the product is and is not approved or authorised for.
• Intended-use statement matching the use you are purchasing for.
• Label and leaflet wording reviewed against your destination market’s requirements.
• A named quality contact at the manufacturer, not only a sales contact.

Procurement Takeaway

Exosomes and PDRN belong in separate lines of enquiry on a procurement list, because they are separate categories with separate regulatory positions. The US FDA has approved no exosome product and no PN or PDRN injectable filler or skin booster. Korea’s MFDS has authorised polynucleotide products through a medical device pathway, and that authorisation applies in Korea. The EU treats exosome-based therapies as ATMPs.

A buyer who can state those three sentences accurately, and who demands the same clarity in writing from every supplier, is operating on evidence. The market for these products is growing, published forecasts project continued expansion, and regulatory attention in the category is more likely to increase than to recede. Documentation you can defend is the only durable position.

AestiSource supplies dermal fillers, skin boosters, and mesotherapy-format products with declared specification values, lot-level documentation, and a written statement of classification and intended use per product. For buyers evaluating exosome-format or PDRN-format products, request the classification and documentation package before committing to an order.